Elizabeth Claire Dees

E. Claire Dees, MD, is a UNC Lineberger Comprehensive Cancer Center member and Professor of Medicine at UNC-Chapel Hill in the Department of Hematology and Oncology. She specializes in breast cancer and early phase clinical trials.

MD, MSc, ScM
Professor; Director, Early Phase Clinical Research and Drug Development, UNC Lineberger; Co-Leader, UNC Lineberger Clinical Research Program
UNC-Chapel Hill
Breast Cancer
Clinical Research
UNC Breast Center

Area of interest

My research focuses on breast cancer and novel therapeutics. I am also interested in studying inter-individual differences in chemotherapy associated toxicity. I am currently the lead investigator or co-investigator for a number of early phase clinical trials of new anti-cancer drugs and combinations for the treatment of patients with refractory solid tumors. I am also the principal investigator for several clinical trials of treatments specifically for early stage and metastatic breast cancer. I am the UNC principal investigator for our Experimental Therapeutics Clinical Trials Network consortium (with Duke and Wash U) and the principal investigator for the cooperative group NRG at UNC. I also serve as a member of the Pharmacology and Pharmacogenomics committee of the cooperative group ALLIANCE. I have been awarded a Patient Oriented Research Career Development Award from the NIH, and R21 grant, foundation grants, and numerous clinical trials contracts. I have authored or co-authored more than 80 original research articles.

I am an experienced medical oncologist and clinical trialist. I am a Professor of Medicine at the University of North Carolina School of Medicine, and a member of UNC Lineberger Comprehensive Cancer Center and the UNC Breast Center. I founded our Developmental Therapeutics (Phase I trials) Working Group at UNC-LCCC, and now direct the early phase clinical trials program, and the breast cancer clinical trials group. I co-lead the LCCC Clinical Research Program. My research focuses on early phase clinical trials of novel therapeutics, especially those focused on breast cancer. I have been the principal investigator for over 100 trials including 10 currently open early phase trials. I am the PI at UNC for the current Duke-UNC-Wash U Partnership in the ETCTN (UM1 grant), as well as a co-investigator on our NCTN grant and site PI for NRG. I have authored or co-authored over 85 papers. I am a member of the CALGB (ALLIANCE) pharmacogenomics and pharmacology committee, and have been a member of ASCO program committees, ABIM Medical Oncology Board Certification committee, peer review panels for DOD, Komen, and NIH, and also an ad hoc reviewer for a number of journals. I have co-mentored a number of fellows in oncology and pharmacology.

Awards and Honors

  • UNC Health Care and Faculty Physicians Award for Carolina Care Excellence, 2019, 2018, 2017, 2015
  • Forbes™ Top 27 Breast Cancer Experts in the Country, 2017
  • Best Doctors in America®, 2017, 2015, 2014, 2012, 2007
  • Komen Scientific Advisory Council member 2010-present
  • 2010 Fellow, Academic Leadership Program
  • 2007 UNC Planetree Physician Champion Award
  • 2002 K23 Patient Oriented Career Development Award
  • 2001 Doris Duke Clinical Scientist Development Award
  • I am the UNC PI for the Duke-UNC-Wash U Partnership in the ETCTN (UM1 grant), as well as a co-investigator on our NCTN grant and site PI for NRG
  • Find publications on PubMed